Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Drug Des Devel Ther · 2017 · PMC5628681 · PMID 29033544

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

did not reach statistical significancep =0.087so close (0.05 < p ≤ 0.1)

There was a trend toward improvement in WAP score at Week 12 in the 100-mg arm compared to placebo, but it did not reach statistical significance (49.1% vs 39.6%, p =0.087).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.